The string of megadeals announced in the first half of 2024 reflect a growing confidence among US dealmakers. But can the bull run be sustained?
Megadeals were firmly on the agenda in H1 as more stable inflation and...more
9/30/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
Global Dealmaking ,
Investment ,
Investors ,
Lenders ,
Mergers ,
Regulatory Agenda ,
Sellers
Global M&A activity continued to make slow progress in 2023, with stubbornly high interest rates and stringent financing conditions stifling market confidence. Nearly US$3.2 trillion of M&A deals were announced last year—a...more
2/16/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Competition ,
EU ,
Federal Trade Commission (FTC) ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Private Equity ,
Sellers ,
Technology
Ongoing uncertainty hampers dealmaking in second quarter of the year, but mining megadeals and the race for clean energy offer a ray of hope.
Global dealmakers had a lot to contend with in the second quarter of this year....more
8/15/2023
/ Acquisitions ,
Buyers ,
EU ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Private Equity Firms ,
Private Equity Funds ,
Sellers
Against the odds, dealmakers put in a solid performance in 2022, but this year has seen a slow start as buyers in the US M&A market clamor for much needed regulatory clarity -
Global M&A markets gave both optimists and...more
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
Following on from two robust first quarters, global M&A activity succumbed to prolonged market uncertainty in the third quarter. A total of 5,163 deals worth a total of US$731.3 billion changed hands during the quarter...more
As predicted in our previous M&A report, 2022 has not lived up to the runaway performance of 2021. As activity—still at impressive levels considering everything that has been thrown at the deal market—takes a breather, we...more
9/13/2022
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
EBITDA ,
Global Dealmaking ,
High Yield Bonds ,
Interest Rates ,
Leveraged Loans ,
Mergers ,
Private Equity
Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more
8/23/2022
/ Acquisitions ,
Capital Markets ,
Deal Price ,
Domestic Dealmaking ,
EBITDA ,
Environmental Social & Governance (ESG) ,
Fair Market Value ,
Global Dealmaking ,
Greenwashing ,
Market Price ,
Mergers ,
Popular ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Dealmaking failed to reach the highs of the previous year as rising inflation and a challenging financing environment put some deals under question -
Global dealmaking continued its bumpy return to pre-pandemic levels in...more
While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year -
Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more
4/8/2022
/ Acquisitions ,
Activision ,
Banking Sector ,
Canada ,
Coronavirus/COVID-19 ,
Gaming ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Real Estate Market ,
Software ,
Technology ,
Video Games
M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more
Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record -
The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges -
US M&A progressed steadily through the first half of 2021....more
8/10/2021
/ Acquisitions ,
Biden Administration ,
CFIUS ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Enforcement ,
Global Dealmaking ,
Investment ,
Liquidity ,
Mergers ,
National Security ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets ,
Technology Sector ,
Vaccinations
A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record
Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more
Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery -
The global pharma, medical and biotech (PMB) sector saw US$95.4 billion in deal...more
A majority of dealmakers say their companies are focused on defense or survival, but about a quarter are actively pursuing growth.
According to Mergermarket, the value of US M&A in the second quarter of 2020 was lower...more